This presentation contains forward-looking statements, including statements about our prospects, products, growth projections, competitive position, potential regulatory filings, and agency actions, and the anticipated development, timing, data readouts, and therapeutic scope of programs in our clinical pipeline. These forward-looking statements may be accompanied by such words as "anticipate," "believe," "estimate,"
"expect," "forecast," "intend," "may," "plan," "project," "target," "will", and other words and terms of similar
meaning. You should not place undue reliance on these statements.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including the safety and efficacy of our product candidates, product competition, market acceptance, the occurrence of adverse safety events with our products or product candidates, clinical trials risk, adverse market and economic conditions, regulatory uncertainty, our dependence on collaborations and other third parties over which we may not always have full control, failure to comply with government regulation, our ability to protect our intellectual property rights, and have sufficient rights to market our products and services together with the cost of doing so, problems with our manufacturing processes and our reliance on third parties, the potential impact of the ongoing COVID-19 pandemic, our ability to attract and retain qualified personnel, our level of indebtedness, environmental risks, change of control provisions in our collaborations, and the other risks and uncertainties that are described in the Risk Factors section of our most recent annual or quarterly report and in other reports we have filed with the SEC.
These statements are based on our current beliefs and expectations and speak only as of the date of this presentation. We do not undertake any obligation to publicly update any forward-looking statements.
backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent - that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies.
Travere is Positioned for Sustainable Growth and Rare Disease Leadership
Patient-inspired culture rooted in personal rare disease experience
Integrated operations with clinical development and commercial expertise in rare disease
Diversified pipeline of potential first-in-class programs targeting rare diseases with no or limited treatment options currently available
Commercial organization prepared for successful launches from pipeline
First launch of sparsentan expected in 1Q23*
Potential opportunity for multiple commercial products and significant value creation
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Travere Therapeutics Inc. published this content on 09 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 January 2023 14:38:11 UTC.
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Companyâs Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. It is also engaged in the identification of potential small molecule therapeutics for Alagille syndrome (ALGS).
TRAVERE THERAPEUTICS, INC. 
